Related Experiment Video

Updated: Oct 13, 2025

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

Anti-angiogenic peptides application in cancer therapy; a review

Alireza Shoari1, Farnaz Khodabakhsh2, Reza Ahangari Cohan3

  • 1Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R. Iran.

Research in Pharmaceutical Sciences
|November 11, 2021
PubMed

Insights

This review explores anti-angiogenic peptides for cancer therapy. These peptides offer high specificity and low toxicity, representing a promising advancement over conventional treatments for angiogenesis-dependent diseases.

Area of Science:

  • Oncology and Pharmacology
  • Biotechnology and Drug Discovery

Background:

  • Cancer progression is significantly driven by excessive angiogenesis.
  • Conventional cancer therapies face limitations due to drug resistance and lack of specificity.
  • There is a critical need for novel anti-angiogenic agents with improved efficacy and reduced side effects.

Purpose of the Study:

  • To review the design and application of anti-angiogenic peptides in cancer therapy.
  • To highlight peptides derived from various sources, including nanobodies, mimotopes, phage displays, and natural resources.
  • To emphasize the potential of peptides as targeted therapeutics for angiogenesis-dependent diseases.

Main Methods:

  • Literature review focusing on anti-angiogenic peptide research.
  • Analysis of peptide design, screening, and derivation strategies.
  • Evaluation of peptide characteristics such as cancer cell penetration, specificity, and toxicity.

Main Results:

  • Peptides demonstrate significant therapeutic potential due to their favorable properties.
  • Various methods for generating anti-angiogenic peptides are discussed.
  • Peptides offer a promising alternative or adjunct to existing cancer treatments.

Conclusions:

  • Anti-angiogenic peptides are a key area of development in cancer therapy.
  • Their high specificity, low toxicity, and cancer cell penetration make them valuable therapeutics.
  • Further research into peptide-based therapies is warranted for angiogenesis-dependent cancers.
Keywords:
AngiogenesisCancerNanobodiesNatural resourcePeptidePhage display

More Related Videos

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.2K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
726
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K